(Q34519945)

2 August 2017

title

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

pulmonary tuberculosis

1 reference

Helen M McIlleron

9

0 references

Salome Charalambous

6

object named as

Salome Charalambous

1 reference

2 August 2017

7

Mark Hatherill

1 reference

2 August 2017

5

Gavin J Churchyard

1 reference

2 August 2017

8

Hennie Geldenhuys

1 reference

2 August 2017

21

Timothy D McHugh

1 reference

2 August 2017

Amina Jindani

1

1 reference

2 August 2017

Thomas S Harrison

2

1 reference

2 August 2017

Andrew J Nunn

3

1 reference

2 August 2017

Patrick P J Phillips

4

1 reference

2 August 2017

Simbarashe P Zvada

10

1 reference

2 August 2017

Stanley Mungofa

11

1 reference

2 August 2017

Nasir A Shah

12

1 reference

2 August 2017

Simukai Zizhou

13

1 reference

2 August 2017

Lloyd Magweta

14

1 reference

2 August 2017

James Shepherd

15

1 reference

2 August 2017

Sambayawo Nyirenda

16

1 reference

2 August 2017

Janneke H van Dijk

17

1 reference

2 August 2017

Heather E Clouting

18

1 reference

2 August 2017

David Coleman

19

1 reference

2 August 2017

Anna L E Bateson

20

1 reference

2 August 2017

Philip D Butcher

22

1 reference

2 August 2017

Denny A Mitchison

23

1 reference

2 August 2017

RIFAQUIN Trial Team

24

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2014

1 reference

The New England Journal of Medicine

2 August 2017

published in

1 reference

2 August 2017

volume

371

1 reference

2 August 2017

issue

17

1 reference

2 August 2017

page(s)

1599-1608

1 reference

Combination antifungal therapy for cryptococcal meningitis

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Multiplicity in randomised trials II: subgroup and interim analyses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Practical guidelines for multiplicity adjustment in clinical trials.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Timing of relapse in short-course chemotherapy trials for tuberculosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Multiplicity in randomised trials I: endpoints and treatments.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4233406

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

27 October 2018

1 reference

12 December 2020

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

12 December 2020

Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1314210

1 reference

2 August 2017

1 reference

2 August 2017

1 reference